Merck & Co. will leverage Mayo Clinic’s extensive multimodal data sets—including laboratory results and clinical insights—to validate AI-driven models and enhance drug development strategies.

Initial efforts will focus on high-need indications such as inflammatory bowel disease, atopic dermatitis and multiple sclerosis, aiming to accelerate the discovery of more effective targeted therapies.

This first-scale alliance with a global biopharmaceutical firm is poised to streamline Merck’s R&D process, potentially reducing development timelines and improving long-term growth prospects.